COMING SOON – IJTLD Open

The Union's new Open Access journal

You are here:

IJTLD Open

Launching in January 2024

IJTLD OPEN has the same values, scope and Editorial Board as the IJTLD, with an identical peer review process and acceptance criteria. Our scope includes TB and its risk factors and co-morbidities alongside related areas of lung health such as asthma, bronchiectasis, COVID-19, COPD, child lung health and the hazards of tobacco and air pollution.

Our aim is the continuing education of academics, clinicians and other health personnel, and the dissemination of the most up-to-date information in the fields of respiratory diseases and lung health.

Call for papers

We invite authors with OA funding to submit their papers (including Original Articles, Letters and Case Series) to IJTLD OPEN.

We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.

This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.

For all queries please e-mail the Editorial Office

Information for Authors

Before submission, authors should follow the instructions to authors to help speed through peer review - see Instructions for Authors

Authors for both IJTLD and IJTLD OPEN should submit their manuscripts via the same portal and manuscripts will be evaluated solely on scientific merit. Go to Manuscript Central at http://mc.manuscriptcentral.com/ijtld

The only change will occur after a paper has been accepted: authors with funding for OA will be published in IJTLD OPEN; those without will be published in the IJTLD.

Sponsorship

Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.

Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.

All content will be freely available on Ingenta.com and on the open access repository PubMed Central. We will also have regular mailings to highlight the latest sponsored content.

Fast-Track Articles

In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles: